Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Robert W. Baird Cuts SFBC to Neutral from Outperform

Robert W. Baird cut its rating on SFBC International(SFCC) to neutral from outperform, explaining that "material risks have emerged" at the drug development company.

Bloomberg claims to have uncovered evidence that SFBC mishandled a trial in Montreal, allowing a TB-infected patient to inappropriately enter a trial and infect others, among other things.

Analyst Eric Coldwell says that new information gleaned during a recent conference call was "disconcerting." He identified several new misstatements from management that further shake his confidence in the company. He also believes SFBC inappropriately treated patients in Miami.

blog comments powered by Disqus